The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma

Edward Fox, Jesse T. Torbert, Anne Marie Martin, Arthur P. Staddon, Joseph L. Finstein, Richard D. Lackman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Currently, the only treatment available for recurrent/metastatic chondrosarcoma is further surgical resection. Fluoroquinolones have shown toxicity in immature cartilage, inducing apoptosis and inhibiting the proliferation of human chondrosarcoma cells. Since previous studies suggested that ciprofloxacin and paclitaxel act synergistically in slowing the growth of chondrosarcoma in vitro, we investigated their effects on human recurrent/metastatic chondrosarcoma. Four patients received oral ciprofloxacin (750 mg twice daily) and intravenous paclitaxel (90 mg/m2) for 6-8 weeks of each cycle. Patient 1 remained stable 32.8 weeks after initiation of treatment. Patient 2 showed a 60% decrease in tumor growth but progressed by 10.3 weeks. Patient 3 progressed over 9 weeks, remained stable for 16 months, and then progressed after treatment with paclitaxel was discontinued. Patient 4 had three lesions: the recurrent lesion progressed despite treatment, showing an 8% increase in growth; one metastatic lesion remained stable (18 weeks), and the second metastatic lesion progressed. Gene expression profiling of normal articular cartilage and human chondrosarcoma cells exposed to ciprofloxacin showed differential expression of the genes DDX5, MYST2, ISGF3, APC, RPL3, EIF4C2, and ERH, all of which are involved in cell proliferation, cell-cycle regulation, or apoptosis.

Original languageEnglish (US)
Pages (from-to)516-522
Number of pages7
JournalCommunity Oncology
Volume2
Issue number6
DOIs
StatePublished - Jan 1 2005

Fingerprint

Chondrosarcoma
Ciprofloxacin
Paclitaxel
Growth
Apoptosis
Fluoroquinolones
Articular Cartilage
Gene Expression Profiling
Therapeutics
Cartilage
Cell Cycle
Cell Proliferation
Gene Expression
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Fox, E., Torbert, J. T., Martin, A. M., Staddon, A. P., Finstein, J. L., & Lackman, R. D. (2005). The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma. Community Oncology, 2(6), 516-522. https://doi.org/10.1016/S1548-5315(11)70634-9
Fox, Edward ; Torbert, Jesse T. ; Martin, Anne Marie ; Staddon, Arthur P. ; Finstein, Joseph L. ; Lackman, Richard D. / The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma. In: Community Oncology. 2005 ; Vol. 2, No. 6. pp. 516-522.
@article{f3e316e6cf61432bba0bb201b9ff2b5c,
title = "The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma",
abstract = "Currently, the only treatment available for recurrent/metastatic chondrosarcoma is further surgical resection. Fluoroquinolones have shown toxicity in immature cartilage, inducing apoptosis and inhibiting the proliferation of human chondrosarcoma cells. Since previous studies suggested that ciprofloxacin and paclitaxel act synergistically in slowing the growth of chondrosarcoma in vitro, we investigated their effects on human recurrent/metastatic chondrosarcoma. Four patients received oral ciprofloxacin (750 mg twice daily) and intravenous paclitaxel (90 mg/m2) for 6-8 weeks of each cycle. Patient 1 remained stable 32.8 weeks after initiation of treatment. Patient 2 showed a 60{\%} decrease in tumor growth but progressed by 10.3 weeks. Patient 3 progressed over 9 weeks, remained stable for 16 months, and then progressed after treatment with paclitaxel was discontinued. Patient 4 had three lesions: the recurrent lesion progressed despite treatment, showing an 8{\%} increase in growth; one metastatic lesion remained stable (18 weeks), and the second metastatic lesion progressed. Gene expression profiling of normal articular cartilage and human chondrosarcoma cells exposed to ciprofloxacin showed differential expression of the genes DDX5, MYST2, ISGF3, APC, RPL3, EIF4C2, and ERH, all of which are involved in cell proliferation, cell-cycle regulation, or apoptosis.",
author = "Edward Fox and Torbert, {Jesse T.} and Martin, {Anne Marie} and Staddon, {Arthur P.} and Finstein, {Joseph L.} and Lackman, {Richard D.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/S1548-5315(11)70634-9",
language = "English (US)",
volume = "2",
pages = "516--522",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "6",

}

Fox, E, Torbert, JT, Martin, AM, Staddon, AP, Finstein, JL & Lackman, RD 2005, 'The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma', Community Oncology, vol. 2, no. 6, pp. 516-522. https://doi.org/10.1016/S1548-5315(11)70634-9

The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma. / Fox, Edward; Torbert, Jesse T.; Martin, Anne Marie; Staddon, Arthur P.; Finstein, Joseph L.; Lackman, Richard D.

In: Community Oncology, Vol. 2, No. 6, 01.01.2005, p. 516-522.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma

AU - Fox, Edward

AU - Torbert, Jesse T.

AU - Martin, Anne Marie

AU - Staddon, Arthur P.

AU - Finstein, Joseph L.

AU - Lackman, Richard D.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Currently, the only treatment available for recurrent/metastatic chondrosarcoma is further surgical resection. Fluoroquinolones have shown toxicity in immature cartilage, inducing apoptosis and inhibiting the proliferation of human chondrosarcoma cells. Since previous studies suggested that ciprofloxacin and paclitaxel act synergistically in slowing the growth of chondrosarcoma in vitro, we investigated their effects on human recurrent/metastatic chondrosarcoma. Four patients received oral ciprofloxacin (750 mg twice daily) and intravenous paclitaxel (90 mg/m2) for 6-8 weeks of each cycle. Patient 1 remained stable 32.8 weeks after initiation of treatment. Patient 2 showed a 60% decrease in tumor growth but progressed by 10.3 weeks. Patient 3 progressed over 9 weeks, remained stable for 16 months, and then progressed after treatment with paclitaxel was discontinued. Patient 4 had three lesions: the recurrent lesion progressed despite treatment, showing an 8% increase in growth; one metastatic lesion remained stable (18 weeks), and the second metastatic lesion progressed. Gene expression profiling of normal articular cartilage and human chondrosarcoma cells exposed to ciprofloxacin showed differential expression of the genes DDX5, MYST2, ISGF3, APC, RPL3, EIF4C2, and ERH, all of which are involved in cell proliferation, cell-cycle regulation, or apoptosis.

AB - Currently, the only treatment available for recurrent/metastatic chondrosarcoma is further surgical resection. Fluoroquinolones have shown toxicity in immature cartilage, inducing apoptosis and inhibiting the proliferation of human chondrosarcoma cells. Since previous studies suggested that ciprofloxacin and paclitaxel act synergistically in slowing the growth of chondrosarcoma in vitro, we investigated their effects on human recurrent/metastatic chondrosarcoma. Four patients received oral ciprofloxacin (750 mg twice daily) and intravenous paclitaxel (90 mg/m2) for 6-8 weeks of each cycle. Patient 1 remained stable 32.8 weeks after initiation of treatment. Patient 2 showed a 60% decrease in tumor growth but progressed by 10.3 weeks. Patient 3 progressed over 9 weeks, remained stable for 16 months, and then progressed after treatment with paclitaxel was discontinued. Patient 4 had three lesions: the recurrent lesion progressed despite treatment, showing an 8% increase in growth; one metastatic lesion remained stable (18 weeks), and the second metastatic lesion progressed. Gene expression profiling of normal articular cartilage and human chondrosarcoma cells exposed to ciprofloxacin showed differential expression of the genes DDX5, MYST2, ISGF3, APC, RPL3, EIF4C2, and ERH, all of which are involved in cell proliferation, cell-cycle regulation, or apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=28244494129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244494129&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70634-9

DO - 10.1016/S1548-5315(11)70634-9

M3 - Article

AN - SCOPUS:28244494129

VL - 2

SP - 516

EP - 522

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 6

ER -